ILR ECG Analyzer†,4
Up to 76%
fewer false-positive episodes · high sensitivity5
A manufacturer-agnostic second layer on top of device filters, so your team can trust the signal and focus on clinically meaningful events.
Learn more →The Active Shield
Behind every cardiac outcome is a team navigating too many portals, too many alerts, and too much administrative drag. Implicity exists to support those teams.
We are Implicity. The Active Shield.
Clinical evidence
Cardiac remote monitoring built on FDA-cleared algorithms and backed by published clinical data.
Outcomes
26%
reduction in mortality associated with Implicity vs. conventional manufacturer-specific remote monitoring in ICD patients.2
ILR ECG Analyzer†
Up to 76%
fewer false-positive ILR episodes while maintaining high sensitivity, with our FDA-cleared ILR ECG Analyzer†.4–6
SignalHF‡
35 days
average advance alert before a heart failure hospitalization, with 60% sensitivity, from FDA-cleared SignalHF‡.1,6
Time saved
300+
hours saved per year at 200 patients, the equivalent of about eight weeks of work.7
Clinical empowerment
Filter the noise with alert-based intelligence.
Implicity helps your team focus on what matters first, without losing sight of any patient. FDA-cleared algorithms flag and prioritize every alert for your team’s review, so clinicians spend their attention on what’s clinically meaningful; the final call always stays with them.
Illustrative only. Every alert is reviewed by your clinical team; not actual patient data or algorithm output.
Why electrophysiologists choose Implicity
MW
Manish Wadhwa, MDElectrophysiologist · SDHV, San Diego
Implicity stands apart for three key reasons: their FDA clearance, their ability to deliver vast amounts of discrete data, and their sophisticated use of AI. It’s not just about the AI they use today, but how that foundation allows for even greater innovation down the line.
01FDA clearance
02Discrete data at scale
03Sophisticated AI
The platform
The core technologies that power our platform.
Built for the people doing the work
One shield.
Every role in the program.
Trust the signal.
Act faster on what matters.
FDA-cleared algorithms prioritize meaningful events within an alert-based model, so you see what matters and can act with confidence when it counts.
Learn MoreWhy Implicity
Intelligence that protects.
Technology that scales.
Clinical empowerment
Filter the noise with alert-based intelligence.FDA-cleared algorithms help your team focus on what matters first, without losing sight of any patient.
Care for the whole cardiac patient.From device monitoring through HF risk management, in one unified shield.
The complete picture, clearly structured.Direct manufacturer feeds and structured, actionable views.
Operational efficiency
One platform. One workflow.Less manufacturer portal hopping, more time on patients.
Integrates with your existing systems.Including major EHRs, so data flows into the tools your teams already use.
Capture unrealized revenue.A dynamic billing engine that automates key reimbursement workflows.3
Predictable implementation
Designed with security at our core.Dual ISO certifications and FDA-cleared algorithms, built to meet rigorous expectations.
Easy to deploy. Quick to value.Efficient implementation paired with continuous partnership.
We are invested in your outcomes.Clear, ongoing reporting shows exactly how Implicity is driving performance.
Continuous improvement
Built with you, for you.Workflow upgrades every two weeks, driven by your daily reality on the front lines.
Unifying your entire patient population.Ambulatory monitoring rolling out, for one shield across the continuum of cardiac care.
Always moving Intelligent Remote Monitoring forward.Advancing clinical intelligence and workflow automation.
ISO 27001ISO 13485HIPAA compliantSOC 2 readyFDA-cleared algorithmsAs featured in
Recognized by the press and our industry.
Award Winner 2026
About Implicity
One patient.
A stroke that never should have happened.
Implicity was co-founded by Dr. Arnaud Rosier to solve a problem he encountered in his practice as an electrophysiologist.
“Every day I needed to log on 5 different portals, with 5 different passwords to read, interpret and analyze 5 different ways of displaying CIEDs data and alerts.
I wanted to offer the best healthcare to my patients and be excellent in my mission as an electrophysiologist but my Remote Monitoring tools were outdated. I faced daily IT and data processing issues which made RM practice very complex. Also, no Remote Monitoring billing system was available and billing for patients follow-up was a manual and an extremely tedious process.”
AR
Dr. Arnaud RosierCo-founder & Electrophysiologist, Implicity
Request a demo
See Implicity in action.
Tell us a bit about your program and a member of our team will reach out to schedule a walkthrough tailored to your clinic.
IMP1020202601 IMPLICITY®, Inc. a Delaware corporation with offices located at 185 Alewife Brook Pkwy 210, Cambridge, MA 02138 USA, file number 5917973.
- †IM007 ILR ECG Analyzer is an FDA cleared Class II medical device, see the instructions for use for more information.
- ‡SignalHF is an FDA cleared Class II medical device, see the instructions for use for more information.
- 1SignalHF is an FDA-cleared Class II medical device; see the instructions for use for more information. SignalHF is compatible with ICD/CRT-D from Medtronic, Boston Scientific and Biotronik and IPG/CRT-P from Medtronic and Biotronik able to measure thoracic impedance.
- 2Varma N, Marijon E, Vicaut É, et al. Impact of a universal monitoring system (“third party”) on outcomes of ICD patients: a nationwide study. Heart Rhythm. 2025;22(10):2661-2668. doi:10.1016/j.hrthm.2024.11.029. Observational data; results reflect an association.
- 3Data on file: data analysis observed in a cardiology practice in Oklahoma City, OK, January 2025 to January 2026. Individual results may vary.
- 4IM007 ILR ECG Analyzer is an FDA-cleared Class II medical device (Manufacturer: Implicity), intended for qualified healthcare professionals for assessment of arrhythmias in implantable cardiac monitor (ICM) ECG data from the following major manufacturers: Abbott, Biotronik, Boston Scientific and Medtronic. It operates as a second-layer analysis of residual alerts remaining after manufacturer filtering. The next-generation algorithm received FDA 510(k) clearance in July 2026 and is now commercially available to U.S. customers. Not for use in life-supporting or sustaining systems or ECG monitor and alarm devices. Results are advisory only, in conjunction with physician knowledge and other diagnostic information. See the instructions for use for more information.
- 5Varma N, Wadhwa M, Lazarus A, Faedda G, Mabo P, Crespin E. Performance of a cloud-based AI solution for reducing false positive alerts in implantable cardiac monitors detected episodes. Europace. 2026;28(Suppl 1):euag105.043.
- 6Varma N, Boveda S, Ibnouhsein I, Faedda G, Rosier A, Singh J. Heart failure events prediction algorithm for patients implanted with multi-brand CIED. Europace. 2024;26(Suppl 1):euae102.553. doi:10.1093/europace/euae102.553
- 7Internal simulation (data on file) modeled on 2,500 patients across American medical centers over 12 months, showing a 37.6% alert reclassification rate. This translates to savings of over 300 hours per year (approximately eight weeks of work) for a 200-patient clinic, and one full-time equivalent per year for a 1,000-patient clinic. Modeled data, not clinical outcomes.
- 8Durand J, Bonnet JL, Lazarus A, Taieb J, Rosier A, Mittal S. Using technology to improve reconnection to remote monitoring in cardiac implantable electronic device patients. Cardiovasc Digit Health J. 2023;5(1):1-7. doi:10.1016/j.cvdhj.2023.11.020
- 9Data on file: data analysis observed in a cardiology practice in Oklahoma City, OK, January 2025 to January 2026. Single-site data. Individual results may vary.
- 10IM009 AF Alert Management is designed to align with U.S. atrial fibrillation treatment guidelines; it is advisory only and does not replace physician judgment. Singh JP, Gentils M, Faedda G, Lazarus A, Mignot N, Mabo P. A Smart-Alert Algorithm for personalized management of CIED-detected atrial fibrillation: a multicenter study. Heart Rhythm. 2026. doi:10.1016/j.hrthm.2026.03.1725.
The Implicity platform is a clinical decision support device and is in no way intended to replace the responsibility or clinical judgment of the practitioner. It is designed to optimize data workflows and support medical expertise in patient management.